The HIV-1 envelope glycoprotein trimer is poorly immunogenic because it is covered by a
dense glycan shield. As a result, recombinant Env glycoproteins generally elicit inadequate …

In HIV-1 vaccine research, native-like, soluble envelope glycoprotein SOSIP trimers are
widely used for immunizing animals. The epitopes of autologous neutralizing antibodies …

Recombinant soluble HIV-1 envelope glycoprotein (Env) SOSIP trimers are a design
platform for inducing broadly neutralizing antibodies (bNAbs) by vaccination. To date, these …

Influenza virus neuraminidase (NA) is a major antiviral drug target and has recently
reemerged as a key target of antibody-mediated protective immunity. Here we show that …

Technological advances in immunology, protein design, and genetic delivery have unlocked
new possibilities for vaccine concepts and delivery technologies that were previously …

The formation of a correctly folded and natively glycosylated HIV-1 viral spike is dependent
on protease cleavage of the gp160 precursor protein in the Golgi apparatus. Cleavage …

Soluble envelope (Env) trimers, stabilized in a prefusion-closed conformation, can elicit
neutralizing responses against HIV-1 strains closely related to the immunizing trimer …

The human immunodeficiency virus (HIV) infection of the immune cells expressing the
cluster of differentiation 4 cell surface glycoprotein (CD4+ cells) causes progressive decline …

We describe the properties of BG505 SOSIP. 664 HIV‐1 envelope glycoprotein trimers
produced under current Good Manufacturing Practice (cGMP) conditions. These proteins are …

Recombinant HIV-1 envelope (Env) glycoproteins of ever-increasing sophistication have
been evaluated as vaccine candidates for over 30 years. Structurally defined mimics of …